Market News & Trends
Vetter Marks the Start of New Clinical Site Construction with Groundbreaking Ceremony
Pharmaceutical service provider expands its footprint in the greater Chicago area Production site expected to be fully operational by the end of 2029 Modern site…
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
TARPON SPRINGS, Fla., Allarity Therapeutics, Inc. (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor…
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
RESEARCH TRIANGLE PARK, N.C., Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and…
Positive Top Line Results from Confirmatory Efficacy Study for Proposed Biosimilar to Xolair (omalizumab)
REYKJAVIK, Iceland and PISCATAWAY, N.J. and LONDON, Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients…
Sever Pharma Solutions Announces Commercialization of New Aseptic Fill and Finish Line for Prefilled Syringes in Malmö, Sweden
MALMÖ, SWEDEN– Sever Pharma Solutions, a leading CDMO, proudly announces the commercialization of its new state-of-the-art aseptic fill and finish line for prefilled syringes, capable…
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
HOUSTON, Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced…
Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program
Saint-Louis, France and Dublin, Ireland, Priothera, a late-stage biopharma company pioneering the development of mocravimod, a novel oral sphingosine 1 phosphate (S1P) receptor modulator, to treat…
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company’s Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
BOSTON, Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for…
BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Review marks…
Longeveron Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-months Laromestrocel Biological License Application (BLA) submission for…
Neurona Doses First Patient in Phase 1/2 Trial of NRTX-1001 Cell Therapy in Adults with Drug-Resistant, Bilateral Mesial Temporal Lobe Epilepsy (MTLE)
- First patient received bilateral administration of NRTX-1001; no significant surgical complications or adverse events reported to date - - Trial funded by a…
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
New Good Manufacturing Practice (GMP) Solution Center in Wyandotte, Michigan expands BASF’s existing network of poloxamers sites Production capabilities are unique to industry and enable…
Veranova Devens Site Breaks Ground on ADC Facility Expansion
Devens, MA, USA — Government officials, industry leaders, and local business representatives gathered yesterday to mark the groundbreaking of Veranova’s latest expansion at its Devens,…
Symbiotic.blue Launches to Combine Oxford and Cambridge Scientific Brain Power with Bioentrepreneurial Leadership to Reinvent AI Drug Discovery
Symbiotic.blue, the UK’s newest Techbio company has launched to innovate a next-generation artificial intelligence-driven drug discovery (AIDD) platform by combining the power of generative AI…
Synfini Inc. and O2nix Bio Announce Strategic Collaboration to Develop Novel Cancer Therapeutics Targeting FTSJ1
MENLO PARK, Calif. and CAMBRIDGE, Mass.,Synfini Inc., a leader in AI-driven drug discovery, and O2nix Bio, a pioneering biotech company advancing prooxidant therapies, today announced…
Sanner has officially launched manufacturing operations in Greensboro, North Carolina
The new facility is dedicated to producing critical injection-molded components for medical devices and pharmaceutical packaging, as well as desiccant solutions. This expansion reflects Sanner’s…
Kindeva joins forces with Rocket Science Health to pioneer new Intranasal Delivery Platform
Kindeva, a global CDMO and drug delivery expert, and Rocket Science Health (RSH), a Canadian technology healthcare company, have joined forces to find partners to…
Lifecore Biomedical Signs New 10-Year Commercial Manufacturing and Supply Agreement with Key Existing Custome
CHASKA, Minn., Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has signed a new 10-year commercial manufacturing…
Northstrive Biosciences Announces Initiation of Phase II of Collaboration to Develop AI Powered Therapies for Obesity and Cardiometabolic Disease
Northstrive Biosciences and Yuva Biosciences previously announced a collaboration leveraging MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.
Captain T Cell Joins Bayer Co.Lab Berlin to Accelerate Autologous and Allogeneic TCR-T Cell Therapy Programs for Cancer Patients
Captain T Cell a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected for residency…